Edition:
United Kingdom

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

1.62USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,128
52-wk High
$35.00
52-wk Low
$1.51

Chart for

About

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies,... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $35.38
Shares Outstanding(Mil.): 15.59
Dividend: 29.10
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Altimmune reports Q3 loss per share $2.05

* Altimmune announces third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Altimmune to provide corporate update at Rodman & Renshaw global investment conference

* Altimmune to provide corporate update at the Rodman & Renshaw global investment conference Source text for Eikon: Further company coverage:

06 Sep 2017

BRIEF-Altimmune submits investigational new drug application for Nasovax for phase 2 trial preparation

* Altimmune submits investigational new drug application for Nasovax in preparation for Phase 2 trial

21 Aug 2017

BRIEF-Altimmune announces $14.7 million Series B preferred stock offering

* Altimmune announces $14.7 million Series B preferred stock offering

17 Aug 2017

BRIEF-Altimmune posts Q2 loss of $0.26 per share

* Altimmune announces second quarter 2017 financial results and provides corporate update

10 Aug 2017

Competitors

Earnings vs. Estimates